Médecine Intensive-Réanimation, Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation, 5, Place d'Arsonval, 69437, Lyon Cedex 03, France.
Faculté de Médecine Lyon-Est, Université de Lyon, Lyon, France.
Intensive Care Med. 2022 Nov;48(11):1563-1572. doi: 10.1007/s00134-022-06872-1. Epub 2022 Sep 14.
To determine whether remote ischemic conditioning (RECO), compared to standard care, limits the severity and the consequences of multiple organ failure in patients with septic shock.
The RECO-Sepsis trial, a prospective, multicenter, randomized, open-label, parallel group trial with blinded assessment of the outcome, was conducted at six intensive care units in France in adult patients with septic shock. Within 12 h after the onset of septic shock, patients were randomized (1:1 ratio) to receive either RECO applied by inflating/deflating (200/0 mmHg for 5/5 min) 4 times a cuff around an arm or a sham procedure every 12 h for 24 h. The primary endpoint was the severity of multiple organ failure assessed by the mean daily Sequential Organ Failure Assessment (SOFA) score from inclusion to the fourth day after inclusion (day 4). Patients were followed for 90 days.
Among 180 randomized patients, 178 completed the trial (RECO group: 87; control group: 91) and were included in the intention-to-treat analysis (108 men [60.7%], median age 68 [59-75] years). There was no significant difference in the mean daily SOFA score between the intervention group and the control group (7.2 points [5.2-10.7] versus 7.6 points [4.9-10.7], respectively; p = 0.919). Cumulative mortality within 90 days was 27.6% in the RECO group and 39.6% control group (Log-rank test, p = 0.10; adjusted hazard ratio 0.59, 95% CI, 0.35 to 0.99; p = 0.049).
In patients with septic shock, RECO failed to reduce the severity of organ failures assessed by mean daily SOFA score from inclusion to day 4. Adequately powered trials are needed to assess potential delayed benefits of RECO.
确定远程缺血预处理(RECO)与标准治疗相比,是否能减轻脓毒性休克患者多器官衰竭的严重程度和后果。
RECO-Sepsis 试验是一项前瞻性、多中心、随机、开放标签、平行组试验,结局评估采用盲法,在法国六家重症监护病房进行,纳入的成年脓毒性休克患者在发病后 12 小时内,按 1:1 比例随机(随机分配)接受 RECO 治疗(充气/放气 200/0mmHg 各 5/5 分钟,共 4 次)或假处理(每 12 小时 1 次,共 24 小时)。主要终点是从纳入到纳入后第 4 天的平均每日序贯器官衰竭评估(SOFA)评分来评估多器官衰竭的严重程度(第 4 天)。患者随访 90 天。
在 180 名随机患者中,178 名完成了试验(RECO 组 87 名,对照组 91 名),并纳入意向治疗分析(108 名男性[60.7%],中位年龄 68[59-75]岁)。干预组和对照组的平均每日 SOFA 评分无显著差异(分别为 7.2 分[5.2-10.7]和 7.6 分[4.9-10.7];p=0.919)。RECO 组 90 天内累积死亡率为 27.6%,对照组为 39.6%(对数秩检验,p=0.10;调整后的危险比 0.59,95%CI,0.35 至 0.99;p=0.049)。
在脓毒性休克患者中,RECO 未能降低从纳入到第 4 天的平均每日 SOFA 评分评估的器官衰竭严重程度。需要进行充分的效能试验来评估 RECO 的潜在延迟获益。